Drug intelligence / Profile preview

Lactogemikan

Development stage: Phase 2
Lead developer: Pescado
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactogemikan is a probiotic supplement developed by Pescado Pharmaceuticals that contains 10 billion CFU of the bacterium *Lactobacillus plantarum* per tablet. It is primarily investigated for its therapeutic potential in patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) undergoing hemodialysis. The supplement's mechanism of action involves modulating the gut microbiota to reduce the production and systemic accumulation of gut-derived uremic toxins, such as indoxyl sulfate and p-cresyl sulfate. By enhancing intestinal barrier integrity and reducing systemic inflammation and oxidative stress, Lactogemikan aims to slow the progression of kidney disease and improve the nutritional and metabolic health of renal patients.

Brand names: Lactogemikan

Beyond the preview

Go deeper on Lactogemikan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactogemikan.

Explore the full profile